Xalkori or Crizotinib was approved only one year ago for lung cancer patients with ALK-type cell mutation. I would like to find actual survival data (statistics) presumably based on earlier approval trials and recent data. Where is this published?
Reply # - August 4, 2012, 01:37 PM
Xalkori is pretty new, so long-term survival data is not complete, but you can find some data on response in this post by Dr. West:
You can also go to clinicaltrials.gov, to look for trials which have posted results:
At present, the trials showing results are preliminary studies which do not address survival.
Reply # - August 4, 2012, 08:27 PM
Dr. Alice Shaw from Massachusetts General Hospital presented some work at ASCO 2011 that looked retrospectively at outcomes for ALK-positive patients who did vs. did not receive XALKORI (crizotinib), noting that survival was longer in the ALK-positive patients who had received it.
You can see the one and two year survival stats in the link, and the median survival (the point at which halfof the patients had died and half remain alive) hadn't been reached yet...nice to see.